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Introduction
In the early 1980s, methodology was established to allow for 
culture of pluripotent embryonic stem cells (ESCs) isolated 
from the inner cell mass of mouse blastocysts (for review see 
Glaser et al., 2005). Gene targeting in ESCs was soon thereafter 
achieved through homologous recombination, followed by gen-
eration of mouse strains from such manipulated ESCs. Occa-
sionally, gene targeting results in early embryonic lethality, 
which precludes understanding of the contribution of genes to 
subsequent developmental processes including de novo blood 
vessel formation (vasculogenesis) and formation of new blood 
vessels from preexisting vessels (angiogenesis).
Blood vessels are essential for the delivery of nutrients 
and oxygen to tissues, as well as for removal of waste products. 
All blood vessels share a number of basic features, although 
the detailed gene expression pattern, morphology, and function 
vary between different vascular beds (e.g., arteries, veins, and 
capillaries). The inside of blood vessels is lined with endothe-
lium, a thin layer of endothelial cells (ECs), which separates 
the blood from tissues. The outside of the endothelium is cov-
ered with a specialized layer of connective tissue (the base-
ment membrane) followed by a layer of mural cells (pericytes 
and vascular smooth muscle cells). Angiogenesis is a tightly 
controlled process where EC proliferation and migration is 
regulated by secreted factors as well as by surrounding cells 
and matrix. There are currently considerable efforts invested 
into the development of drugs aimed to control blood vessel 
growth in conditions such as ischemia and cancer, character-
ized by defi  cient or excessive vessel growth, respectively. To 
this end, it is essential to create easily accessible models by 
which vessel development can be both manipulated and studied 
at high resolution.
Vascular development and sprouting 
angiogenesis in embryoid bodies
The isolation of EC lines and the establishment of conditions 
required for their maintenance in cell culture represents a mile-
stone in the vascular biology fi  eld (Gimbrone et al., 1973). 
However, such cultures do not provide a proper microenviron-
ment, involving three-dimensional (3D) interactions between 
ECs and adjacent supporting cells and matrix that are known to 
be absolutely vital in regulation of vascular processes. In con-
trast, cultures of human and murine ESCs possess the capacity 
to differentiate into most if not all major cell lineages (Thomson 
et al., 1998), creating an environment with parallel development 
of several cell types. Thus, in differentiating ESCs assembled 
into embryoid bodies (EBs), vascular development occurs in a 
context of continuous interactions with adjacent non-ECs. The 
fi  rst indication that EC development and subsequent vascular 
morphogenesis in differentiating ESC cultures proceed in an 
in vivo–like fashion was provided by Doetschman et al. (1985).
Formation of EBs can be controlled through aggregation 
of ESCs in hanging drops (Fig. 1, A and B), after the removal of 
feeder cells and leukemia inhibitory factor that otherwise are 
used to keep the ESCs pluripotent. The hanging drop culture 
proceeds for a few days to allow EB growth and differentiation, 
followed by seeding into a two-dimensional (2D) culture (Fig. 1, 
C and E), or into a 3D collagen gel (Fig. 1, D and F). For more 
information on EB culture procedures, see Jakobsson et al. 
(2006) (detailed protocols will be made available upon request 
to the authors). At d 3 of differentiation, the onset of vasculo-
genesis is demonstrated by the presence of a precursor common 
for endothelial and hematopoietic cells, the hemangioblast. The 
hemangioblast, which expresses T cell acute leukemia 1/stem 
cell leukemia (TAL/SCL), vascular endothelial growth factor 
receptor (VEGFR)-2, and brachyury, has also been detected in 
human EBs (Choi et al., 1998; Kennedy et al., 2007). Subse-
quently, hemangioblasts will be committed to either the hema-
topoietic or the EC lineage. The EC precursors, the angioblasts, 
undergo sequential maturation to eventually express a set of 
markers characteristic for mature ECs such as VEGFR-2, CD31, 
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vascular endothelial (VE)– cadherin, Tie-1, and Tie-2. Angio-
blast development in EBs thus closely mimics the in vivo matu-
ration process (Vittet et al., 1996).
The primary vascular plexus in the EB is remodeled from 
d 6 and onwards, by sprouting angiogenesis. This process is regu-
lated by growth factors, which may be produced endogenously or 
added in as exogenous factors. Also without growth factor treat-
ment but in the presence of 15% serum, vascular development is 
evident by the presence of blood islands that differentiate to form 
small networks of ECs located in the center of the EB. Addition of 
growth factors stimulates further expansion of the endothelium. 
There is a distinct morphology of the vascular plexus formed in 2D 
EB cultures dependent on the growth factor present in the culture; 
VEGF isoforms VEGF-A121 and VEGF-A165, fi  broblast growth 
factor-2, and platelet-derived growth factor (PDGF)-BB each en-
hance vessel formation in a distinct pattern. Typically, VEGF-A165 
stimulates the formation of a peripheral capillary plexus in 2D EB 
cultures (Fig. 1, C and E) (Jakobsson et al., 2006).
Invasive angiogenesis in 3D collagen gels is preferen-
tially induced by VEGF-A165 and manifested around d 8 by 
the formation of EC sprouts protruding from the central core 
of the EB. The stalk cells are guided by tip cells with numer-
ous fi  lopodia, a process with striking similarities to vascular 
development in zebra fi  sh and the retina (Fig. 1, D and F; and 
Fig. 2 A) (Lawson and Weinstein, 2002; Gerhardt et al., 2003). 
Subsequently, the sprouts branch and occasional tip cells fuse 
with adjacent vessels to form networks. The EC sprouts are 
surrounded by perivascular cells that share features such as 
morphology (i.e., close apposition to the endothelial cells) and 
protein expression pattern (expressing nerve-glia2 [NG2] and/or 
α-smooth muscle actin [αSMA]) with pericytes seen in vivo 
(Fig. 2 A). Furthermore, the vessels are enclosed by a vascular 
basement membrane whose detailed composition, dynamics, and 
Figure 1.  Outline of 2D and 3D EB models for vasculogenesis and angio-
genesis. Stem cells are trypsinized (d 0), (A) and aggregated to create EBs, 
in drops hanging from the lid of a Petri dish (B). Aggregation can also oc-
cur spontaneously by seeding ESCs in suspension in a nonadhesive Petri 
dish, resulting in EBs of variable size. After 4 d, EBs are seeded on a tissue 
culture slide (2D), (C) or alternatively embedded in a 3D collagen gel (D). 
Addition of VEGF induces formation of a peripheral vascular plexus in 2D 
(C and E) and endothelial cell sprouts (“angiogenesis”) in 3D (D and F) 
(bottom panel in F adopted from Magnusson et al., [2005]). Whole-mount 
stainings for CD31 of 2D (E) or 3D (F) EBs at d 10 of differentiation, un-
treated (Ctrl, top) or induced with VEGF (bottom). Bars, 500 μm.
Figure 2.  Angiogenic sprouts invade the surrounding matrix. (A) Features 
of blood vessel sprouts formed in 3D collagen matrix in response to VEGF. 
Expression is shown of the endothelial cell marker CD31/platelet-endothelial 
cell adhesion molecule (PECAM; red), the pericyte markers αSMA (green, 
top), and NG2 (green, bottom middle). Hoechst 33342 was used to indi-
cate nuclei (blue). Lumen formation is evident in larger vessels (left, cross 
section [z-stack] of a sprout [d 18] generated by confocal microscopy). The 
tip cell at the front of growing sprouts send out ﬁ  lopodia to sense growth 
factor gradients. Occasional ﬁ  lopodia are also detected on stalk cells that 
lack pericyte coverage. Bars, 10 μm. (B) Knockout EBs and the assembly 
of chimeric EBs. Cells deﬁ  cient in production of HS (Ndst1/2
−/−) or lack-
ing VEGFR-2 (vegfr2
−/−) do not form vascular sprouts in the EB model. 
However, chimeric EBs generated by mixing of the two ESC lines before EB 
formation respond to VEGF and form sprouts. In the chimeras, the endothe-
lial cells (CD31; red) are derived from Ndst1/2
−/− cells expressing VEGFR-2, 
whereas functional HS is provided by pericytes (αSMA; green) lacking 
VEGFR-2 (Jakobsson et al., 2006). Bar, 300 μm. STEM CELL MODELS IN VASCULAR BIOLOGY • JAKOBSSON ET AL. 753
function in the EBs remain to be described. Lumen formation 
is detectable at about d 10 of EB differentiation, and occasion-
ally a mature lumen is evident at d 12 (Fig. 2 A). Subsequently, 
large lumenized vascular networks become established. It is an 
interesting possibility that the EB endothelium has the capacity 
to undergo arterial/venous specifi  cation, as endothelial cells 
formed from ESCs in vitro specifi  cally express either ephrin B2 
or EphB4, which are markers for arterial and venous endothe-
lium, respectively (Muller-Ehmsen et al., 2006).
Embryoid bodies; beyond early lethality 
of transgenic animals
Inactivation of genes with a vascular function (vegfr2, vegfa, 
VE-cadherin, or pdgfrß) results in similar phenotypes in the EB 
model as in vivo, with regard to temporal effects on develop-
ment and consequences for EC morphology (Table I) (Olsson 
et al., 2006). For example, deletion of VEGF-A, one of the main 
VEGFR-2 ligands, results in an arrest in vascular development 
and remodeling in vivo as well as in vitro (Ng et al., 2004). The 
EB model is particularly suitable in this context because it al-
lows rapid and easy testing of the unique contribution of dif-
ferent VEGF-A isoforms to vascular development. Accordingly, 
treatment of VEGF-A–defi  cient EBs with purifi  ed VEGF-A165 
rescued EC morphogenesis (Bautch et al., 2000), in agreement 
with the fact that mice expressing only VEGF-A165 display 
normal vascular development. In certain cases, data generated 
using in vivo models have been extended by studies performed 
in different ESC-based culture models. For example, VEGFR-2 
was shown by differentiation of vegfr2
−/− ESCs to be required 
for vascular morphogenesis but not essential for early endothe-
lial and hematopoietic cell commitment (Schuh et al., 1999). 
Furthermore, a number of gene deletions have resulted in devel-
opmental arrest before the onset of vasculogenesis, for example 
due to defects in implantation. However, by generation of ESCs 
from recombinant blastocysts, critical stages incompatible with 
in vivo growth may be studied in the EB model (see Table I for 
a comparison of vascular phenotypes in gene-targeted embryos 
and EBs).
A severe developmental phenotype (lethal before gas-
trulation) is caused by simultaneous deletion of the enzymes 
N-deacetylase/N-sulfotransferase 1 and 2 (NDST1/2), central to 
the synthesis of heparan sulfate (HS) (Holmborn et al., 2004). 
Proteins modifi  ed by attachment of HS, so-called   proteoglycans, 
are essential co-receptors for many tyrosine kinase receptors, 
including VEGFR-2. Deletion of the NDST1/2 enzymes se-
verely hampers ESC differentiation with a close to complete 
loss of vascular development (Fig. 2). However, rescue of vas-
cular development was achieved in chimeric EB cultures com-
posed of a mix of Ndst1/2
−/− and vegfr2
−/− ESCs (Jakobsson et al., 
2006). Here, endothelial cells derived from the HS-defi  cient 
Ndst1/2
−/− stem cells (expressing VEGFR-2) were comple-
mented by normal HS produced by pericytes derived form the 
vegfr2
−/− ESCs (Fig. 2). This exemplifi  es the versatility of the 
EB model, which allows combinations of knock-out ESCs to 
study the requirement for genes in subpopulations of cells during 
cell specifi  cation and development, to unravel new mechanisms 
in cell communication.
Restrictions of the EB model
Although ESCs have the capacity to produce cells of essen-
tially any type, it is likely that complex processes that require 
progression through several developmental stages may be under-
represented. For example, although blood EC development is 
faithfully reproduced, the subsequent differentiation of lym-
phatic ECs from blood vessels is diffi  cult to control (Kreuger 
et al., 2006). Furthermore, EBs lack blood fl  ow, and dependent 
Table I. Vascular phenotypes in mouse embryos and EBs, as a consequence of speciﬁ  c gene targeting
Phenotype
Genotype Embryo EB
vegfr2
−/− aE8.5–9.5. Defective blood-island formation and vasculogenesis 
 (Shalaby et al., 1995)
Defective EC development and vascular remodeling 
 (Jakobsson et al., 2006)
vegfa
+/− E11–12. Defective vascular development 
 (Carmeliet et al., 1996; Ferrara et al., 1996)
Reduced EC development and vascular remodeling; partial 
 rescue by exogenous VEGF (Bautch et al., 2000)
vegfa
−/− E9.5–10.5. Generated by aggregation of ESCs with tetraploid 
 embryos. More severely affected than vegfa
+/− embryos 
 (Carmeliet et al., 1996)
Attenuated EC development and vascular remodeling; 
 partial rescue by exogenous VEGF 
 (Bautch et al., 2000; Ng et al., 2004)
VE-cadherin
−/− E9.5. Defective vascular development and angiogenesis 
  (Carmeliet et al., 1999)
Defective vascular formation and morphogenesis 
 (Vittet et al., 1997)
N-cadherin
−/− E10. Impaired angiogenesis, defective yolk sac vasculature 
  (Radice et al., 1997)
Reduced pericyte coating, otherwise intact vascular sprouting 
 and remodeling (Tillet et al., 2005)
pdgfrβ
−/− Lethal shortly before birth, hemorrhagic (Soriano, 1994). 
  Loss of vSMC recruitment to small arteries in limb, heart and skin 
 (Hellström et al., 1999)
Loss of vSMC/pericyte recruitment to angiogenic sprouts 
 (Rolny et al., 2006)
Ndst1/2
−/− Lethal before gastrulation (Holmborn et al., 2004) Attenuated vascular development; rescue by HS presented in 
 trans by non-EC (Jakobsson et al., 2006)
fgfr1
−/− E9.5. Reduced blood-island formation (Deng et al., 1994) Exaggerated vascularization and angiogenic sprouting in the 
 absence of exogenous growth factors (Magnusson et al., 2005)
β1integrin
−/− E5.5 (Fässler and Meyer, 1995) Poor vessel branching, disturbed VEGF-induced morphogenesis 
 (Bloch et al., 1997)
aIndicates time point of embryonic lethality.JCB • VOLUME 177 • NUMBER 5 • 2007  754
on the process under study, this aspect may be vital as fl  ow-
induced shear stress infl  uences remodeling of the vascular 
system (Nguyen et al., 2006). Another drawback is that the de-
tailed organization of vascular structures in individual EBs is 
much more variable compared with the precise vascular pat-
terning in embryos. In the authors’ experience, the serum cho-
sen for the embryoid body cultures infl  uences the properties 
of the cultures with regard to spontaneous vascularization, or 
alternatively, the ability to respond to exogenously added growth 
factors. The ongoing development of serum-free culture con-
ditions might therefore contribute to an increased stability of 
the system. On the other hand, the model as such appears very 
stable as ESC lines of different genetic background show re-
markably similar properties with regard to vascular develop-
ment and sprouting angiogenesis.
Manipulated ESCs in vascular 
biology research
As described above, the fl  exibility of the EB model is remark-
able due to the fact that ESCs can be derived from all types of 
genetically engineered mice. Thus, ESC-based models may in 
the future be used widely to complement and occasionally even 
replace animal experimentation, especially when very early 
embryonic lethality becomes a severe limitation (see Table I). 
ESCs from transgenic mice and gene-targeted mutant mice can 
be evaluated independently, or in combination, by generating 
chimeric cultures of two or more different ESC types (Jakobsson 
et al., 2006). Inducible gene expression and deletion systems, 
such as the Tetracyclin-On and -Off expression systems, and the 
site-specifi  c DNA recombinase system Cre/loxP, in combina-
tion with labeling of cells by expression of reporter genes (e.g., 
β-galactosidase or fl  uorescent proteins) will allow clonal analy-
sis and lineage tracing similar to what can be done in animal 
models (Glaser et al., 2005; Ueno and Weissman, 2006). 
Several ESCs with fl  uorescent reporters under the control of 
EC-specifi  c promoters have already been created, constituting 
powerful tools for live imaging at single-cell or even subcellular 
resolution by confocal or two-photon excitation microscopy 
(Fraser et al., 2005).
Generation of homozygous gene deletions and recom-
binant animals is expensive, time consuming, and laborious.   
Gene silencing can instead be achieved by RNA-interference, 
where RNAi can be delivered to both murine and human ESCs 
through lentiviral transduction (Zaehres et al., 2005). Because 
RNAi delivery can be traced and enriched through selection for 
reporter gene expression, a very high degree of silencing can be 
attained. Moreover, previously reported problems with clonal 
selection and loss of expression during differentiation of ES 
cells appear to be circumvented when using lentivirus as a strat-
egy for introduction of RNAi (see Zaehres et al., 2005 for fur-
ther discussion).
Future perspectives
The fact that stem cells under proper conditions have the ca-
pacity to differentiate into both blood and lymphatic ECs may 
be explored for therapeutic purposes (Nishikawa et al., 1998). 
Importantly, both mouse and human ESCs can be used to generate 
functional ECs contributing to formation of stable vessels that 
connect to the host circulation (Yurugi-Kobayashi et al., 2003; 
Wang et al., 2007). The use of human ESCs for therapeutic 
purposes obviously presents a moral dilemma. Possibly, re-
trieval of ESCs from other locations than the fetus, such as um-
bilical cord blood or amniotic sources may present a feasible 
alternative in the future (Zhang et al., 2006). Furthermore, it is 
an interesting possibility that pathological conditions charac-
terized by impaired blood and lymph vessel function may be 
treated by administration of adult stem cells or progenitors iso-
lated from the patient’s own bone marrow. For a recent review 
on the contribution of circulating stem cells to angiogenesis, 
see Kopp et al. (2006).
Despite striking similarities between mouse and human 
development, numerous therapies developed in mice (e.g., to treat 
diseases such as cancer) have failed when tested in humans. 
A contributing factor to such failures may be genetic differences 
between the species. Because most experimentation on humans 
is prohibited for ethical reasons, preclinical testing has relied 
solely on animal experimentation. In the future, application of 
human ESCs may constitute an additional step in the develop-
ment and testing of drugs, with regard to toxicity and terato-
genic effects. Furthermore, experimentation with human ESCs 
offers means to study human embryonic development. Already, 
homologous recombination and introduction of RNAi have 
been demonstrated in human ESCs, paving the way for new in-
sights in human biology (Zwaka and Thomson, 2003).
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